Announcement • Jul 16
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 4.999999736 billion in funding from Telcon Holdings Co., Ltd. On July 14, 2026, TELCON RF PHARMACEUTICAL. Inc. has closed the transaction. Announcement • Jul 07
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 4.999999736 billion in funding from Telcon Holdings Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. announced that it will issue 2,329,916 new shares at a price of KRW 2,146 per share for the proceeds of KRW 4,999,999,736 on July 6, 2026. The transaction included participation from returning investor Evercore Investment Holdings Co., Ltd. Transaction has been approved by the board of directors. Securities issued will be in lock-up period for 1 year. The transaction is expected to be closed on July 14, 2026. New Risk • Jul 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩15.2b (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (90% increase in shares outstanding). Market cap is less than US$10m (₩15.2b market cap, or US$9.80m).